Loading…
Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX
Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vac...
Saved in:
| Published in: | Vaccine 2004-06, Vol.22 (17), p.2103-2105 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c450t-9f275f2fb5af0e030eacfc952fc2a9b0e07393d920b6979931ba0350fc9d94693 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c450t-9f275f2fb5af0e030eacfc952fc2a9b0e07393d920b6979931ba0350fc9d94693 |
| container_end_page | 2105 |
| container_issue | 17 |
| container_start_page | 2103 |
| container_title | Vaccine |
| container_volume | 22 |
| creator | Kitchener, Scott |
| description | Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded. Incidence data is not available. On investigation of vaccine surveillance reports from Europe following distribution of more than 3 million doses of ARILVAX™, four cases each of YFV-AVD and YFV-AND were found (each 1.3 cases per million doses distributed) for the period 1991 to 2003. The incidence for each is higher after 1996 (2.5 cases per million doses distributed). The incidence of these adverse events appears to be very low with ARILVAX™. Similar incidence data is required from other countries for comparison. |
| doi_str_mv | 10.1016/j.vaccine.2004.01.026 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71932939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X04000702</els_id><sourcerecordid>71932939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-9f275f2fb5af0e030eacfc952fc2a9b0e07393d920b6979931ba0350fc9d94693</originalsourceid><addsrcrecordid>eNqFkV2L1DAUhoMo7rj6E5SA6JWtJ0nTTK5kWL8WBgTRZe9Cmp64GTrtbNLOsv_elCkq3uzV4Rye8_W-hLxkUDJg9ftdebTOhR5LDlCVwErg9SOyYmslCi7Z-jFZ5UpVVAyuz8izlHYAIAXTT8kZk6zSqpYr4q9CchiHMQ6H4KjtW9rj9CdvQ0KbkPqh64a70P-ip612DENP78J4Q8cbpEx9pPc4I9TjEeNC4Tu6-X65vdpcPydPvO0SvljiOfn5-dOPi6_F9tuXy4vNtnCVhLHQnivpuW-k9YAgAK3zTkvuHbe6ySUltGg1h6bWSmvBGgtCQmZaXdVanJO3p7mHONxOmEazn__rOtvjMCWjmBZci4dBprRiIEQGX_8H7oYp9vkJw6RcZxV1zTMlT5SLQ0oRvTnEsLfx3jAws19mZxZNzOyXAWayO7nv1TJ9avbY_u1aDMrAmwWwydnOR9u7kP7hlFpLPZ_54cRhVvcYMJrkAvYO2xDRjaYdwgOn_AaDabV_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1558976962</pqid></control><display><type>article</type><title>Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Kitchener, Scott</creator><creatorcontrib>Kitchener, Scott</creatorcontrib><description>Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded. Incidence data is not available. On investigation of vaccine surveillance reports from Europe following distribution of more than 3 million doses of ARILVAX™, four cases each of YFV-AVD and YFV-AND were found (each 1.3 cases per million doses distributed) for the period 1991 to 2003. The incidence for each is higher after 1996 (2.5 cases per million doses distributed). The incidence of these adverse events appears to be very low with ARILVAX™. Similar incidence data is required from other countries for comparison.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2004.01.026</identifier><identifier>PMID: 15149765</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Applied microbiology ; Arboviroses ; Biological and medical sciences ; Encephalitis ; Encephalomyelitis, Acute Disseminated - epidemiology ; Europe ; Fever ; Fundamental and applied biological sciences. Psychology ; Hepatitis ; Human viral diseases ; Humans ; Immunization ; Incidence ; Infectious diseases ; Medical sciences ; Microbiology ; Multiple Organ Failure - epidemiology ; Neurotropic disease ; Poliomyelitis ; Tetanus ; Tropical diseases ; Tropical viral diseases ; Vaccination ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Attenuated - administration & dosage ; Vaccines, Attenuated - adverse effects ; Vector-borne diseases ; Viral diseases ; Viral Vaccines - administration & dosage ; Viral Vaccines - adverse effects ; Viscerotropic disease ; Yellow fever ; Yellow Fever - prevention & control ; Yellow fever vaccine ; Yellow Fever Vaccine - administration & dosage ; Yellow Fever Vaccine - adverse effects ; Yellow fever virus</subject><ispartof>Vaccine, 2004-06, Vol.22 (17), p.2103-2105</ispartof><rights>2004</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jun 2, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-9f275f2fb5af0e030eacfc952fc2a9b0e07393d920b6979931ba0350fc9d94693</citedby><cites>FETCH-LOGICAL-c450t-9f275f2fb5af0e030eacfc952fc2a9b0e07393d920b6979931ba0350fc9d94693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15778593$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15149765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kitchener, Scott</creatorcontrib><title>Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded. Incidence data is not available. On investigation of vaccine surveillance reports from Europe following distribution of more than 3 million doses of ARILVAX™, four cases each of YFV-AVD and YFV-AND were found (each 1.3 cases per million doses distributed) for the period 1991 to 2003. The incidence for each is higher after 1996 (2.5 cases per million doses distributed). The incidence of these adverse events appears to be very low with ARILVAX™. Similar incidence data is required from other countries for comparison.</description><subject>Applied microbiology</subject><subject>Arboviroses</subject><subject>Biological and medical sciences</subject><subject>Encephalitis</subject><subject>Encephalomyelitis, Acute Disseminated - epidemiology</subject><subject>Europe</subject><subject>Fever</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hepatitis</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization</subject><subject>Incidence</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Multiple Organ Failure - epidemiology</subject><subject>Neurotropic disease</subject><subject>Poliomyelitis</subject><subject>Tetanus</subject><subject>Tropical diseases</subject><subject>Tropical viral diseases</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Attenuated - administration & dosage</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vector-borne diseases</subject><subject>Viral diseases</subject><subject>Viral Vaccines - administration & dosage</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viscerotropic disease</subject><subject>Yellow fever</subject><subject>Yellow Fever - prevention & control</subject><subject>Yellow fever vaccine</subject><subject>Yellow Fever Vaccine - administration & dosage</subject><subject>Yellow Fever Vaccine - adverse effects</subject><subject>Yellow fever virus</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkV2L1DAUhoMo7rj6E5SA6JWtJ0nTTK5kWL8WBgTRZe9Cmp64GTrtbNLOsv_elCkq3uzV4Rye8_W-hLxkUDJg9ftdebTOhR5LDlCVwErg9SOyYmslCi7Z-jFZ5UpVVAyuz8izlHYAIAXTT8kZk6zSqpYr4q9CchiHMQ6H4KjtW9rj9CdvQ0KbkPqh64a70P-ip612DENP78J4Q8cbpEx9pPc4I9TjEeNC4Tu6-X65vdpcPydPvO0SvljiOfn5-dOPi6_F9tuXy4vNtnCVhLHQnivpuW-k9YAgAK3zTkvuHbe6ySUltGg1h6bWSmvBGgtCQmZaXdVanJO3p7mHONxOmEazn__rOtvjMCWjmBZci4dBprRiIEQGX_8H7oYp9vkJw6RcZxV1zTMlT5SLQ0oRvTnEsLfx3jAws19mZxZNzOyXAWayO7nv1TJ9avbY_u1aDMrAmwWwydnOR9u7kP7hlFpLPZ_54cRhVvcYMJrkAvYO2xDRjaYdwgOn_AaDabV_</recordid><startdate>20040602</startdate><enddate>20040602</enddate><creator>Kitchener, Scott</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7U7</scope><scope>7X8</scope></search><sort><creationdate>20040602</creationdate><title>Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX</title><author>Kitchener, Scott</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-9f275f2fb5af0e030eacfc952fc2a9b0e07393d920b6979931ba0350fc9d94693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Applied microbiology</topic><topic>Arboviroses</topic><topic>Biological and medical sciences</topic><topic>Encephalitis</topic><topic>Encephalomyelitis, Acute Disseminated - epidemiology</topic><topic>Europe</topic><topic>Fever</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hepatitis</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization</topic><topic>Incidence</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Multiple Organ Failure - epidemiology</topic><topic>Neurotropic disease</topic><topic>Poliomyelitis</topic><topic>Tetanus</topic><topic>Tropical diseases</topic><topic>Tropical viral diseases</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Attenuated - administration & dosage</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vector-borne diseases</topic><topic>Viral diseases</topic><topic>Viral Vaccines - administration & dosage</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viscerotropic disease</topic><topic>Yellow fever</topic><topic>Yellow Fever - prevention & control</topic><topic>Yellow fever vaccine</topic><topic>Yellow Fever Vaccine - administration & dosage</topic><topic>Yellow Fever Vaccine - adverse effects</topic><topic>Yellow fever virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kitchener, Scott</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Toxicology Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kitchener, Scott</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-06-02</date><risdate>2004</risdate><volume>22</volume><issue>17</issue><spage>2103</spage><epage>2105</epage><pages>2103-2105</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Yellow fever vaccine associated viscerotropic (YFV-AVD) and neurotropic (YFV-AND) diseases have been recently identified in various countries. Previously post-vaccination multiple organ system failure was recognised as a rare serious adverse event of yellow fever vaccination and 21 cases of post-vaccinal (YFV) encephalitis had been recorded. Incidence data is not available. On investigation of vaccine surveillance reports from Europe following distribution of more than 3 million doses of ARILVAX™, four cases each of YFV-AVD and YFV-AND were found (each 1.3 cases per million doses distributed) for the period 1991 to 2003. The incidence for each is higher after 1996 (2.5 cases per million doses distributed). The incidence of these adverse events appears to be very low with ARILVAX™. Similar incidence data is required from other countries for comparison.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15149765</pmid><doi>10.1016/j.vaccine.2004.01.026</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-06, Vol.22 (17), p.2103-2105 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71932939 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Applied microbiology Arboviroses Biological and medical sciences Encephalitis Encephalomyelitis, Acute Disseminated - epidemiology Europe Fever Fundamental and applied biological sciences. Psychology Hepatitis Human viral diseases Humans Immunization Incidence Infectious diseases Medical sciences Microbiology Multiple Organ Failure - epidemiology Neurotropic disease Poliomyelitis Tetanus Tropical diseases Tropical viral diseases Vaccination Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Attenuated - administration & dosage Vaccines, Attenuated - adverse effects Vector-borne diseases Viral diseases Viral Vaccines - administration & dosage Viral Vaccines - adverse effects Viscerotropic disease Yellow fever Yellow Fever - prevention & control Yellow fever vaccine Yellow Fever Vaccine - administration & dosage Yellow Fever Vaccine - adverse effects Yellow fever virus |
| title | Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A07%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Viscerotropic%20and%20neurotropic%20disease%20following%20vaccination%20with%20the%2017D%20yellow%20fever%20vaccine,%20ARILVAX&rft.jtitle=Vaccine&rft.au=Kitchener,%20Scott&rft.date=2004-06-02&rft.volume=22&rft.issue=17&rft.spage=2103&rft.epage=2105&rft.pages=2103-2105&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2004.01.026&rft_dat=%3Cproquest_cross%3E71932939%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-9f275f2fb5af0e030eacfc952fc2a9b0e07393d920b6979931ba0350fc9d94693%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1558976962&rft_id=info:pmid/15149765&rfr_iscdi=true |